Drug misuse - methadone and buprenorphine (TA114)
Fast, easy summary view of NICE guidance on 'drug misuse'
Methadone and buprenorphine (given as a tablet or a liquid) are recommended as treatment options for people who are opioid dependent.
A decision about which is the better treatment should be made on an individual basis, in consultation with the person, taking into account the possible benefits and risks of each treatment for that particular person. If both drugs are likely to have the same benefits and risks, methadone should be given as the first choice.
Different people will need different doses of methadone or buprenorphine. People should take methadone or buprenorphine daily in the presence of their doctor, nurse or community pharmacist for at least the first 3 months of treatment and until they are able to continue their treatment correctly without supervision.
Treatment with methadone or buprenorphine should be given as part of a support programme to help the person manage their opioid dependence.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: drug misuse
This page was last updated: 11 January 2013
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.